Alectinib provides longer symptom improvement than crizotinib in ALK-positive lung cancer

The findings of the ALEX trial presented at the ELCC (European Lung Cancer Congress) 2018 in Geneva, Switzerland, support the use of alectinib as the new standard of care in the frontline treatment of ALK-positive lung cancer. Alectinib was found to provide longer symptom improvement than crizotinib in ALK-positive non-small-cell lung cancer.

What feeling does this article give you?
Joy
Disgust
Fear
Anger
Sadness

#hashtags to follow:

ALEX [+]    ELCC [+]    European Lung Cancer Congress [+]    Geneva [+]    Switzerland [+]    ALK [+]   

More #news: